#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Acute promyelocytic leukaemia Asthma Polyneuropathy Soft tissue sarcoma Bronchopulmonary dysplasia Primary mediastinal large B-cell lymphoma Dupuytren's contracture Palmar-plantar erythrodysaesthesia syndrome Anaemia Oesophageal adenocarcinoma Adenovirus infection Philadelphia positive chronic myeloid leukaemia Fms-like tyrosine kinase 3 positive Thromboangiitis obliterans Plasma cell myeloma refractory More trials…

    Learn about Rare Diseases

    Leiomyosarcoma recurrent – Trials in Disease Waldenstrom’s macroglobulinaemia refractory – Trials in Disease Hypereosinophilic syndrome VEXAS syndrome Synovial sarcoma metastatic Lymphangioma – Diagnostics Alexander disease Synovial sarcoma Von Willebrand’s disease Hepatic angiosarcoma – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Gentamicin Opevesostat Calcifediol Citric Acid Monohydrate Metamizole Ecoo6A Lutetium (177Lu) Oxodotreotide Vibozilimod Amivantamab Prasinezumab TALADEGIB Dotatate Zinc Sulphate Heptahydrate AZD3632 ALN-961583 HYDROXYCHLOROQUINE Zamtocabtagene Autoleucel Pamapimod Abc-23A-116 ALPROSTADIL More therapies…

    Learn about Your Condition

    Basal cell naevus syndrome Osteomyelitis Immune-mediated renal disorder Primary myelofibrosis HIV infection Metastasis Foetal growth restriction Eyelid ptosis Procedural headache Ovarian epithelial cancer Torticollis Gastric cancer Rasmussen encephalitis Hypotonia Breast angiosarcoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institutul National de Diabet, Nutritie si Boli Metabolice…

Institutul National de Diabet, Nutritie si Boli Metabolice “N.C. Paulescu”

Strada Movila Ion 5-7, Bucharest, 020475, Romania

Want to learn more about this study or check if you can participate? Contact us.

  • Zenagamtide Compared with Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

    Recruiting

    3 1 1
    Investigated Diseases:
    • Obesity
    • Overweight
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Semaglutide
    Bulgaria Croatia Germany Hungary Poland Portugal +1

  • Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

    Recruiting

    3 1 1
    Investigated Diseases:
    • Cardiovascular disorder
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Bi 690517
    • Empagliflozin
    Austria Belgium Bulgaria Croatia Czechia Denmark +17

  • Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

    Recruiting

    3 1
    Investigated Diseases:
    • Arteriosclerosis
    Investigated Drugs:
    • Maridebart Cafraglutide
    Austria Belgium Bulgaria Czechia Denmark Finland +12

  • Study on Baxdrostat and Dapagliflozin for Preventing Heart Failure in Patients at High Risk

    Recruiting

    3 1 1
    Investigated Drugs:
    • Baxdrostat
    • Dapagliflozin
    Bulgaria Czechia Denmark France Germany Greece +8

  • Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

    Recruiting

    4 1
    Investigated Drugs:
    • Clazakizumab
    Austria Belgium Bulgaria Croatia Czechia Denmark +16

  • Inclisiran for Preventing Cardiovascular Events in High-Risk Primary Prevention Patients with Atherosclerotic Cardiovascular Disease

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Arteriosclerosis
    Investigated Drugs:
    • Inclisiran
    Austria Belgium Bulgaria Croatia Czechia Denmark +14

  • Study comparing cagrilintide and semaglutide versus tirzepatide in people with type 2 diabetes taking metformin or SGLT2 inhibitor

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Cagrilintide
    • Semaglutide
    • Tirzepatide
    Germany Greece Hungary Poland Romania Spain

  • A study comparing cagrilintide and semaglutide combination to semaglutide, cagrilintide, and placebo in adults with type 2 diabetes on metformin

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Cagrilintide
    • Dapagliflozin
    • Metformin
    Bulgaria Croatia Czechia Denmark Finland Germany +9

  • Study of oral and injectable NNC0487-0111 (Amycretin) to find the best dose for blood sugar control in adults with type 2 diabetes taking metformin with or without SGLT2 inhibitor

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Dapagliflozin Propanediol
    • Metformin Embonate
    Bulgaria Croatia Germany Greece Hungary Poland +3

  • Study on the Effects of Semaglutide on Diabetic Eye Disease in People with Type 2 Diabetes

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Semaglutide
    Bulgaria Czechia Germany Greece Latvia Poland +4
1 2
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!